Neogen reported fiscal fourth-quarter revenue of $225.3 million, with core revenue growth accelerating to 4.3%, its highest rate of fiscal 2026. Food safety revenue totaled $166.8 million and grew 5.8% on a core basis, while adjusted EBITDA rose 12% to $45.4 million. For fiscal 2027, the company forecast revenue of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million, while planning to increase R&D spending by about 50% and invest $25 million in transformation initiatives. Neogen also repaid $20 million of its term loan and expects to use approximately $140 million from the planned Genomics business sale to repay debt and fund investments.
Neogen CorporationRevenue and EBITDA beat expectations, with core growth accelerating and positive FY2027 guidance.